Appetite suppressive effects of yeast hydrolysate on nitric oxide synthase (NOS) expression and vasoactive intestinal peptide (VIP) immunoreactivity in hypothalamus

Phytotherapy Research

Volumn 22, Issue 11, 2008, Pages 1417-1422

  Jung, E Y ^a   Suh, H J ^a   Kim, S Y ^a   Hong, Y S ^b   Kim, M J ^b   Chang, U J ^b  

^a Korea University   (South Korea)

^b Dongduk Women's University   (South Korea)

Author keywords

Food intake; Nitric oxide synthase; Vasoactive intestinal peptide; Yeast hydrolysate

Indexed keywords

NITRIC OXIDE SYNTHASE; PROTEIN HYDROLYSATE; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; YEAST HYDROLYSATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APPETITE; ARTICLE; CONTROLLED STUDY; DIET; FOOD INTAKE; HYPOTHALAMUS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIPID METABOLISM; MALE; NERVE CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SPRAGUE DAWLEY RAT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; YEAST;

ANALYSIS OF VARIANCE; ANIMALS; APPETITE DEPRESSANTS; IMMUNOHISTOCHEMISTRY; LIPIDS; MALE; NITRIC OXIDE SYNTHASE; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; RATS; RATS, SPRAGUE-DAWLEY; VASOACTIVE INTESTINAL PEPTIDE; VENTROMEDIAL HYPOTHALAMIC NUCLEUS; WEIGHT GAIN; YEAST, DRIED;

RATTUS;

EID: 57349174166     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2264     Document Type: Article

References (37)

1. Allison DB, Fontaine KB, Manson JE, Stevens J, Vanitallie TB. 1999. Annual deaths attributable to obesity in the United States. JAMA 282: 1530-1538.
2. Ashur-Fabian O, Giladi E, Furman S et al. 2001. Vasoactive intestinal peptide and related molecules induce nitrite accumulation in the extracellular milieu of rat cerebral cortical cultures. Neurosci Lett 307: 167-170.
3. Astrup A. 2001. Healthy lifestyles in Europe: prevention of obesity and type II diabetes by diet and physical activity. Public Health Nutr 4: 499-515.
4. Baba N, Radwan H, Van Itallie T. 1992. Effects of casein versus soyprotein diets on body composition and serum lipid levels in adult rats. Nutr Res 12: 279-288.
5. Bray GA, Greenway FL. 1999. Current and potential drugs for treatment of obesity. Endocr Rev 20: 805-875.
6. Brenneman DE, Hauser J, Phillips TM, Davidson A, Bassan M, Gozes I. 1999. Vasoactive intestinal peptide: Link between electrical activity and glia-mediated neurotrophism. Ann NY Acad Sci 897: 17-26.
7. Carver JD. 1994. Dietary nucleotides: cellular immune, intestinal and hepatic system effects. J Nutr 124: 144S-148S.
8. Casey GP, Ingledew WM. 1983. High gravity brewing: influence of pitching rate and wort gravity on early yeast viability. J Am Soc Brewing Chem 41: 481-488.
9. Chell M. 1997. New developments in breadmaking. Food Manufact 72: 21-22.
10. Claery MP, Muller S, Lanza-Jacoby S. 1987. Effects of long-term moderate food restriction on growth, serum factors, lipogenic enzymes and adiposity glucose metabolism in lean and obese Zucker rats. J Nutr 117: 355-360.
11. Dobrian AD, Davies MJ, Prewitt RL, Lauterio TJ. 2000. Development of hypertension in a rat model of diet-induced obesity. Hypertension 35: 1009-1015.
12. Fujioka K. 2002. Management of obesity as a chronic disease: nonpharmacologic, pharmacologic, and surgical options. Obes Res 10: 116S-123S.
13. Goodson JL, Adkins-Regan E. 1999. Effect of intraseptal vasotocin and vasoactive intestinal polypeptide infusions on courtship song and aggression in the male zebra finch (Taeniopygia guttata). J Neuroendocrinol 11: 19-25.
14. Huang PL. 2000. Mouse models of nitric oxide synthase deficiency. J Am Soc Nephrol 11: S120-S123.
15. Kaiser PK, Lipton SA. 1990. VIP-mediated increase in cAMP prevents tetrodotoxin-induced retinal ganglion cell death in vitro. Neuron 5: 373-381.
16. Kao YH, Chang HH, Lee MJ, Chen CL. 2006. Tea, obesity, and diabetes. Mol Nutr Food Res 50: 188-210.
17. Keef KD, Shuttleworth CWR, Xue C, Bayguinov O, Publicover NG, Sanders KM. 1994. Relationship between nitric oxide and vasoactive intestinal polypeptide in enteric inhibitory neurotransmission. Neuropharmacology 33: 1303-1314.
18. Kim KM, Chang UJ, Kang DH, Kim JM, Choi YM, Suh HJ. 2004. Yeast hydrolysate reduces body fat of dietary obese rats. Phytother Res 18: 950-953.
19. Kim MJ, Chang UJ, Chung JH, Kim HK, Lim BO, Yamada K, Lim YH, Kang SA. 2005. Dissimilarity in fos and jun immunoreactivity in hypothalamic regions between obese and lean Zucker rats. Biosci Biotechnol Biochem 69: 1982-1984.
20. King H, Aubert RE, Herman WH. 1998. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21: 1414-1431.
21. Kopelman PG. 2000. Obesity as a medical problem. Nature 404: 635-643.
22. Kulkosky PJ, Doyle JS, Cood VI, Glazner GW, Foderaro MA. 1989. Vasoactive intestinal peptide: behavioral effects in the rat and hamster. Pharmacol Biochem Behav 34: 387-393.
23. Mokdad AH, Ford ES, Bowman BA et al. 2000. Diabetes trends in the U.S.: 1990-1998. Diabetes Care 23: 1278-1283.
24. Morley JE. 1987. Neuropeptide regulation of appetite and weight. Endocr Rev 8: 256-287.
25. Morley JE, Flood JF. 1987. An investigation of tolerance to the actions of leptogenic and anorexigenic drugs in mice. Life Sci 41: 2157-2165.
26. Morley JE, Flood JF. 1992. Competitive antagonism of nitric oxide synthetase causes weight loss in mice. Life Sci 51: 1285-1289.
27. Morley JE, Flood JF. 1994. Effect of competitive antagonism of NO synthetase on weight and food intake in obese and diabetic mice. Am J Physiol 266: R164-R168.
28. Morley JE, Horowitz M, Morley PM, Flood JF. 1992. Pituitary adenylate cyclase activating polypeptide (PACAP) reduces food intake in mice. Peptides 13: 1133-1135.
29. Nakanishi N, Nakamura K, Suzuki K, Matsuo Y, Tatara K. 2000. Associations of body mass index and percentage body fat by bioelectrical impedence analysis with cardiovascular risk factors in Japanese male office workers. Ind Health 38: 273-279.
30. Parrish CC, Pathy DA, Angel A. 1990. Dietary fish oils limit adipose tissue hypertrophy in rats. Metabolism 39: 217-219.
31. Peeters K, Berghman LR, Vandesande F. 1998. Comparative distribution of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide immunoreactivity in the chicken forebrain. Ann NY Acad Sci 839: 417-419.
32. Said SI. 1991. Vasoactive intestinal polypeptide: Biological role in health and disease. Trends Endocrinol Metab 2: 107-112.
33. Scherer-Singler U, Vincent SR, Kimura H, McGeer EG. 1983 Demonstration of a unique population of neurons with NADPH-diaphorase histochemistry. J Neurosci Methods 9: 229-234.
34. Shinohara T, Kubodera S, Yanagida F. 2000. Distribution of phenolic yeasts and production of phenolic off-flavors in wine fermentation. J Biosci Bioengineer 90: 90-97.
35. Squadrito F, Calapai G, Cucinotta D et al. 1993. Anorectic activity of NG-nitro-L-arginine, an inhibitor of brain nitric oxide synthase, in obese Zucker rats. Eur J Pharmacol 230: 125-128.
36. Tachibana T, Saito S, Tomonaga S et al. 2003. Intracere- broventricular injection of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibits feeding in chicks. Neurosci Lett 339: 203-206
37. Woods SC, West DB, Stein LJ et al. 1981. Peptides and the control of meal size. Diabetologia 20: 305-313.